WO2006025352A1 - 分画装置 - Google Patents
分画装置 Download PDFInfo
- Publication number
- WO2006025352A1 WO2006025352A1 PCT/JP2005/015704 JP2005015704W WO2006025352A1 WO 2006025352 A1 WO2006025352 A1 WO 2006025352A1 JP 2005015704 W JP2005015704 W JP 2005015704W WO 2006025352 A1 WO2006025352 A1 WO 2006025352A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- fractionation device
- solution
- peptide
- membrane
- Prior art date
Links
- 238000005194 fractionation Methods 0.000 title claims description 57
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 140
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 137
- 239000000243 solution Substances 0.000 claims abstract description 119
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 54
- 229920001477 hydrophilic polymer Polymers 0.000 claims abstract description 32
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 claims abstract description 10
- 102000047279 human B2M Human genes 0.000 claims abstract description 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 8
- 239000012528 membrane Substances 0.000 claims description 137
- 239000012510 hollow fiber Substances 0.000 claims description 81
- 238000001179 sorption measurement Methods 0.000 claims description 76
- 239000000758 substrate Substances 0.000 claims description 50
- 239000007864 aqueous solution Substances 0.000 claims description 38
- 239000000463 material Substances 0.000 claims description 26
- 210000004369 blood Anatomy 0.000 claims description 25
- 239000008280 blood Substances 0.000 claims description 25
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 22
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 21
- 229920001577 copolymer Polymers 0.000 claims description 16
- 108010071390 Serum Albumin Proteins 0.000 claims description 15
- 102000007562 Serum Albumin Human genes 0.000 claims description 15
- 210000002966 serum Anatomy 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 10
- 210000002700 urine Anatomy 0.000 claims description 9
- 230000005855 radiation Effects 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 238000004949 mass spectrometry Methods 0.000 claims description 5
- 210000002381 plasma Anatomy 0.000 claims description 5
- 229920002554 vinyl polymer Polymers 0.000 claims description 3
- 206010003445 Ascites Diseases 0.000 claims 2
- 208000002151 Pleural effusion Diseases 0.000 claims 2
- 210000004381 amniotic fluid Anatomy 0.000 claims 2
- 210000001742 aqueous humor Anatomy 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 2
- 239000000284 extract Substances 0.000 claims 2
- 210000003296 saliva Anatomy 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 210000001138 tear Anatomy 0.000 claims 1
- 238000004458 analytical method Methods 0.000 abstract description 30
- 239000012460 protein solution Substances 0.000 abstract description 13
- 108091003079 Bovine Serum Albumin Proteins 0.000 abstract description 7
- 229940098773 bovine serum albumin Drugs 0.000 abstract 3
- 235000018102 proteins Nutrition 0.000 description 104
- 238000012360 testing method Methods 0.000 description 79
- 238000000926 separation method Methods 0.000 description 64
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 45
- 239000007788 liquid Substances 0.000 description 36
- 238000000034 method Methods 0.000 description 36
- 229920002223 polystyrene Polymers 0.000 description 32
- 239000004793 Polystyrene Substances 0.000 description 31
- 238000011084 recovery Methods 0.000 description 24
- 239000002953 phosphate buffered saline Substances 0.000 description 23
- 230000000052 comparative effect Effects 0.000 description 21
- 102000009027 Albumins Human genes 0.000 description 20
- 108010088751 Albumins Proteins 0.000 description 20
- 229940050528 albumin Drugs 0.000 description 20
- 229920001296 polysiloxane Polymers 0.000 description 18
- 231100000987 absorbed dose Toxicity 0.000 description 17
- 239000011550 stock solution Substances 0.000 description 17
- 108010026552 Proteome Proteins 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- -1 polypropylene Polymers 0.000 description 14
- 239000004743 Polypropylene Substances 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 230000002572 peristaltic effect Effects 0.000 description 11
- 239000012153 distilled water Substances 0.000 description 10
- 229920001155 polypropylene Polymers 0.000 description 10
- 239000000523 sample Substances 0.000 description 9
- 239000002981 blocking agent Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 7
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 239000000178 monomer Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000011002 quantification Methods 0.000 description 7
- 239000000090 biomarker Substances 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 150000002433 hydrophilic molecules Chemical class 0.000 description 6
- 230000002209 hydrophobic effect Effects 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 238000007873 sieving Methods 0.000 description 6
- 230000001954 sterilising effect Effects 0.000 description 6
- 238000004659 sterilization and disinfection Methods 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 229910021642 ultra pure water Inorganic materials 0.000 description 5
- 239000012498 ultrapure water Substances 0.000 description 5
- IUVCFHHAEHNCFT-INIZCTEOSA-N 2-[(1s)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(F)C(OC(C)C)=CC=C1C(C1=C(N)N=CN=C11)=NN1[C@@H](C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC(F)=CC=C2O1 IUVCFHHAEHNCFT-INIZCTEOSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 239000004593 Epoxy Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 238000004382 potting Methods 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000004445 quantitative analysis Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000001020 plasma etching Methods 0.000 description 3
- 238000009832 plasma treatment Methods 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920002492 poly(sulfone) Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000007127 saponification reaction Methods 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 101001033280 Homo sapiens Cytokine receptor common subunit beta Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 108090000901 Transferrin Proteins 0.000 description 2
- 102000004338 Transferrin Human genes 0.000 description 2
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- SOGAXMICEFXMKE-UHFFFAOYSA-N alpha-Methyl-n-butyl acrylate Natural products CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000009881 electrostatic interaction Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 102000055647 human CSF2RB Human genes 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 229920002239 polyacrylonitrile Polymers 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000000575 proteomic method Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000012581 transferrin Substances 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 238000004438 BET method Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920002284 Cellulose triacetate Polymers 0.000 description 1
- 235000003913 Coccoloba uvifera Nutrition 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000014702 Haptoglobin Human genes 0.000 description 1
- 108050005077 Haptoglobin Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical group CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 239000004695 Polyether sulfone Substances 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 1
- 229920003080 Povidone K 25 Polymers 0.000 description 1
- 240000008976 Pterocarpus marsupium Species 0.000 description 1
- JQYMGXZJTCOARG-UHFFFAOYSA-N Reactive blue 2 Chemical compound C1=2C(=O)C3=CC=CC=C3C(=O)C=2C(N)=C(S(O)(=O)=O)C=C1NC(C=C1S(O)(=O)=O)=CC=C1NC(N=1)=NC(Cl)=NC=1NC1=CC=CC(S(O)(=O)=O)=C1 JQYMGXZJTCOARG-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 229920005603 alternating copolymer Polymers 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- DQPBABKTKYNPMH-UHFFFAOYSA-N amino hydrogen sulfate Chemical group NOS(O)(=O)=O DQPBABKTKYNPMH-UHFFFAOYSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000009141 biological interaction Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 238000005537 brownian motion Methods 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- KKCZJYFWIFSQFP-UHFFFAOYSA-N ethyl 2-[[3-(dimethylamino)benzoyl]amino]benzoate Chemical compound CCOC(=O)C1=CC=CC=C1NC(=O)C1=CC=CC(N(C)C)=C1 KKCZJYFWIFSQFP-UHFFFAOYSA-N 0.000 description 1
- 229920001038 ethylene copolymer Polymers 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229920000578 graft copolymer Polymers 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000001698 laser desorption ionisation Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 239000008238 pharmaceutical water Substances 0.000 description 1
- 239000005011 phenolic resin Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229950004354 phosphorylcholine Drugs 0.000 description 1
- 229920000083 poly(allylamine) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920006393 polyether sulfone Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 239000005033 polyvinylidene chloride Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 229920005604 random copolymer Polymers 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical group S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
- 238000001419 two-dimensional polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000012929 ultra trace analysis Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
Definitions
- the present invention relates to a fractionation apparatus for preparing a solution for analysis by separating biological components such as protein and Z or peptide from a solution containing protein and Z or peptide, particularly body fluid such as blood and urine. About.
- proteome analysis research has begun to attract attention as post-genomic research. Since protein, which is a gene product, is thought to be directly linked to the pathology of the disease rather than gene, research results of proteome analysis that comprehensively examines proteins are expected to be widely applicable to diagnosis and treatment. However, it is likely that many powerful etiological proteins and disease-related factors that cannot be discovered by genome analysis can be discovered.
- proteome analysis is due to the fact that high-speed structural analysis using a mass spectrometer (MS) has become technically possible.
- MS mass spectrometer
- Assisted laser desorption ionization time—of—flight mass spectrometry enables high-throughput ultra-trace analysis of polypeptides, enabling identification of even minute amounts of proteins that could be detected conventionally. It has become a powerful tool for exploring disease-related factors.
- proteome analysis The primary purpose of clinical application of proteome analysis is the discovery of biomarker proteins that are induced or lost by disease. Biomarkers behave in relation to pathological conditions, so they can be diagnostic markers and are likely to be drug discovery targets. In other words, the results of proteome analysis are likely to become diagnostic markers and drug discovery targets rather than specific genes, and thus become a biomarker technology for diagnosis and treatment in the post-genomic era. Since it directly leads to benefits that patients can enjoy, such as drug responsiveness evaluation and prediction of side effects, it can be said to play a major role in promoting so-called tailor-made medicine (order-made medicine). [0005] When proteomic analysis (clinical proteomics) is introduced into clinical research, it is required to analyze a large amount of samples quickly and reliably.
- Mass specrometry was the main driving force, and it contributed greatly to the ultra-sensitive and high-throughput characteristics of mass spectrometers.
- the methods and equipment have been improved rapidly, the situation where proteome analysis can be easily and quickly performed in clinical settings is still not possible.
- Human 'protein is estimated to be more than 100,000 species It is said that the protein contained in serum alone is about 10,000 types, and the total serum concentration is about 60-80 mg / mL. is there.
- Serum-rich proteins include albumin (molecular weight: 66 kDa), immunoglobin (150-1000 kDa), transferrin (80 kDa), haptoglobin (> 85 kDa), lipoprotein (several lOOkDa), etc. mg / mL).
- albumin moleukins
- cytokines that are considered to be pathological biomarkers and pathogenesis-related factors exist only in trace amounts (ng / mL).
- the content ratio is actually nano to pico level compared to the high content component of the polymer.
- 70% or more of all types of proteins have a molecular weight of 60 kDa or less, and most of the above-mentioned trace amounts of biomarker proteins are mostly contained in this region (for example, Non-patent Document 1). ). Since these proteins pass through the kidney and are partially excreted in the urine, it is possible to measure not only blood but also urine as a specimen.
- Non-Patent Document 1 for example, Dara Dipore: “Gradiflow” system
- traditional precipitation methods such as Cohn ethanol precipitation
- chromatography There is a method of drawing (for example, Non-Patent Document 2). In general, these techniques have been performed as pretreatment operations for mass spectrometry.
- the blocking agent is a solution of albumin or casein, and is a method for suppressing the adsorption of useful biological components by competitive adsorption. Because of the competitive adsorption, the concentration of the blocking agent is generally higher than the concentration of useful biological components.
- a common non-adsorption treatment on the substrate surface is a hydrophilic treatment on the substrate surface.
- Hydrophilic There are several methods for the conversion process.
- Patent Document 2 describes a method of introducing a hydrophilic compound such as a 2-methacryloyloxychetyl phosphorylcholine copolymer (hereinafter abbreviated as MPC) into a base material by coating treatment.
- Patent Documents 3 and 4 describe methods for introducing a hydrophilic compound by grafting.
- There are methods that directly generate hydrophilic functional groups on the substrate surface such as reactive ion etching, plasma treatment, and ion cluster beam treatment.
- the substrate treated by the conventional substrate surface treatment method has an effect of suppressing the adsorption of biological components when contacted with a high concentration protein or peptide solution.
- a solution containing a large amount of biological components there was still a loss of biological components due to adsorption, which was still insufficient to solve the problem.
- Hydrophilization by hydrophilic polymer grafting improves the hydrophilicity in proportion to the amount of grafting, but when the concentration of the hydrophilic polymer solution to be treated increases, the hydrophilic polymers crosslink three-dimensionally. As a result, the motility of the hydrophilic polymer is lowered! There is a problem that the effect of suppressing the adhesion of biological components is lowered.
- reactive ion etching treatment, plasma treatment, and ion cluster beam treatment can be easily hydrophilized to the outer surface of the base material or one side of the plate-like base material. Since it is difficult to hydrophilize shadowed parts such as beams, it is suitable for hydrophilicizing multiple surfaces such as both sides of a plate-like substrate and inner and outer surfaces of a hollow substrate with a single treatment. Absent.
- the adsorption characteristics of the biological component of the base material depend on the surface state of the part in contact with the biological component. In general, the higher the hydrophilicity of the surface, the more the movement of the hydrophilic molecules immobilized on the surface. The higher the property, the lower the adsorption of biological components to the substrate surface.
- hydrophilic molecules with high mobility eliminate biological components such as proteins and platelets by their molecular motion. Hydrophilicity by reactive ion etching treatment, plasma treatment or ion cluster beam treatment is not As a result of the formation of hydrophilic functional groups such as groups, the mobility of hydrophilic molecules is low compared to hydrophilization by introducing hydrophilic polymers onto the substrate surface. The effect is low and undesirable. Furthermore, since the substrate may be denatured because it may become high temperature during the treatment, it is preferable.
- Patent Document 2 Japanese Patent Laid-Open No. 2003-130882
- Patent Document 3 Japanese Patent Laid-Open No. 58-40323
- Patent Document 4 Japanese Patent No. 3297707
- Non-Patent Literature 1 Anderson 'NL (Anderson NL), Anderson' NG (Anderson, NG), "The Human 'Plasma Plasma Proteome: History ⁇ ⁇ ⁇ Character ⁇ ⁇ ⁇ And' Diagnos Aitug 'Pros Hegu (Thehuman plasma proteome: history, character, and diagnostic prospects)], Molecular & Cellular Prot eomics, (USA), The American American Society 1 Fo One Biochemistry 1 The American Society for Biochemistry and Molecular Biology, Inc., 2002, Vol. 1, p845-867.
- Non-patent document 2 edited by the Japanese Biochemical Society, "Seminar of New Chemistry Experiment (Part 1) Protein (1) Separation, Purification, Properties", Tokyo Chemical Doujin, 1990
- the present invention employs the following means.
- Protein and Z or peptide fractionating apparatus wherein at least a partial force of the surface of the substrate in contact with the protein and Z or peptide is contacted with 1000 gZml of urine serum albumin solution Fractionation device with urine serum albumin adsorbed on the surface of 50 ng Zcm 2 or less.
- a protein and Z or peptide fractionating device wherein at least a part of the substrate surface in contact with the protein and Z or peptide is separated from human j8 2-microglobulin at a concentration of 200 ng / ml on the substrate surface.
- a fractionation apparatus wherein the amount of human j8 2-microglobulin adsorbed to the substrate is 3 ng / C m 2 or less when brought into contact with an aqueous protein solution having a concentration of 10 ⁇ g / ml ushi serum albumin.
- Protein and Z or peptide fractionating device a supply means for supplying a solution containing the protein and Z or peptide, a means for separating the protein and Z or peptide from the solution, and the protein in the solution
- a fractionation device having means for concentrating Z or peptide, wherein at least a part of the surface of the substrate in contact with the protein and Z or peptide in the fractionation device is grafted with a hydrophilic polymer.
- FIG. 1 is a schematic view of a fractionation apparatus used in Example A1 of the present invention.
- the meanings of the symbols in the figure are as follows.
- the protein and Z or peptide fractionating device referred to in the present invention is a device for separating these according to molecular weight or according to the characteristics of the protein or peptide.
- the apparatus includes a supply means for supplying a protein or peptide sample and a separation means for performing separation.
- Specimens such as serum, plasma, urine, and other body fluids, artificially prepared solutions containing proteins or peptides, and culture supernatants generated by cell culture can be used at the same concentration or pH buffer.
- the specimen When diluted with a solution or the like and introduced into the supply means, the specimen is transported by the mobile phase and separated by a separation means equipped with a membrane, gel, and adsorbent installed in the flow path of the mobile phase.
- the solution containing the target protein or peptide separated by the fractionation apparatus of the present invention is quantified by ultraviolet absorption, fluorescence, colorimetry, or the like, or the water contained with the protein or peptide is removed as necessary. In this way, it is concentrated, or a certain amount is collected or collected.
- the means for the quantification, concentration, fractionation, and collection steps do not necessarily have to be integrated with the separation step, but the separation means and at least one of the quantification, concentration, fractionation, and collection are at least one.
- a device is preferred in which the means are further connected. If it is necessary to prepare a high concentration protein or peptide solution due to the requirements of the analytical device that is performed after separating and recovering the protein or peptide, the separation device is followed by a concentration device followed by a concentration device. Is preferred.
- the means for transporting the protein or peptide using the mobile phase is not particularly limited, and examples thereof include a tube pump, a gear pump, a diaphragm pump, and a syringe pump as a flow path including tubes, pipes, and grooves.
- the powerful apparatus has means for separating the protein, means for concentrating the protein, and means for selecting the means for collecting the protein obtained by fractionation, and further feeding the protein solution. It is preferable to have a means
- proteins with molecular weight of 60,000 or more correspond to albumin, immunoglobulin, transferrin, etc. in the case of blood. In the case of blood, such proteins are present in a high content with respect to the entire protein component.
- ushi serum albumin having a molecular weight close to 60,000 was used as an index.
- a protein with a molecular weight of less than 150,000 is a protein with a relatively low molecular weight, and if it is blood, its presence is low relative to the total protein, but there are many types.
- the fractionation device of the present invention has a separation means
- a solution containing a protein or peptide is used.
- the liquid may be diluted during the separation process. For example, if the sample is separated by a membrane, the solvent is usually reduced. As the concentration of protein or peptide increases, deposits accumulate on the membrane surface, causing clogging of the membrane pores and reducing separation efficiency. To avoid this, diluting solution may be added to prevent the protein concentration from increasing.
- the main concentrating operations include solvent evaporation or lyophilization by heating or decompression, removal of solvent by filtration or dialysis using a separation membrane that preferentially permeates solvent molecules, and absorption of solvents such as water-absorbing gels.
- fractionation device of the present invention has means for performing these operations!
- the base material with which the protein or peptide of the present invention is contacted includes means for supplying a sample containing the protein or peptide, and any treatment of separation, adsorption, quantification, concentration, fractionation, and collection.
- the means for performing the above are constituent materials that come into contact with a solution containing a protein or peptide at a slippage.
- it is preferable that at least a part of the surface of the base material in contact with the specimen is hydrophilized, and it is most preferable that all the base material surfaces be hydrophilized as much as possible. .
- the material constituting the substrate is not particularly limited, but a polymer material that is easy to chemically process and surface-modify and that can be mass-produced at low cost such as extrusion molding or injection molding is preferable.
- high molecular weight materials include polypropylene, polyethylene, polystyrene, polycarbonate, polymethyl methacrylate, polysulfone, polyethersulfone, polyurethane, polychlorinated bur, polyvinylidene chloride, polyacrylonitrile, cellulose, cellulose acetate.
- Cellulose triacetate, polyamide, polyimide, polytetrafluoroethylene, vinyl Examples include, but are not limited to, alcohol, ethylene copolymer, silicone rubber, epoxy resin, phenol resin, and the like.
- the fractionation device of the present invention by providing a surface on which the protein or peptide is difficult to adsorb on at least a part of the surface of the base material that is in contact with the protein or peptide, not only the adsorption loss can be suppressed, but further It is important to be able to suppress a decrease in separation performance due to adsorption / deposition / clogging of protein or peptide as an action. As a result, a high recovery rate was achieved. Surface characteristics to achieve this, ⁇ shea serum albumin to 0.
- 01cm 2 or more 10 cm 2 or less range to 1000 mu g / ml of ⁇ shea serum albumin solution and contacting the Kino the substrate surface of the substrate surface
- the surface has an adsorption amount of 50 ngZcm 2 or less.
- 8 2-microglobulin at a concentration of 200 ng / ml and ushi serum albumin at a concentration of 10 g / ml Surface with globulin adsorption of 3 ng / cm 2 or less.
- Such surface properties are evaluated by the following method.
- BSA ushi serum albumin
- PBS water (-) powder from Nissui Pharmaceutical Co., Ltd.
- PBS phosphate buffered saline
- the surface in contact with the BSA solution is actually the surface in contact with the protein solution through the pretreatment of the protein.
- the BSA is adsorbed to the cross section. Will not be evaluated.
- the surface area if the substrate is not a separation membrane or a concentrated membrane, if the center line average roughness of the substrate surface is less than 0.1 m, the increase in the area due to surface irregularities is not taken into account. When the center line average roughness is 0.1 m or more The increase in area due to surface irregularities will be taken into account. Centerline average roughness is measured by the method described in Appendix 2 of JIS-B 0601. The surface area considering surface irregularities can be measured by a gas adsorption method such as the BET method or a three-dimensional shape measuring microscope such as Keyence's ultra-deep microscope “VK9500”.
- the membrane area when the base material is a hollow fiber separation membrane or a hollow fiber concentration membrane is calculated as follows. Filter using a module filled with 1.5 m 2 of the target membrane with a 5% by weight BSA aqueous solution adjusted to 37 ° C and pH 7.2 under the conditions of solution flow rate 200 ml Zmin and filtration flow rate 15 ml Zmin.
- BSA sieving coefficient of BSA 30 minutes after the start of filtration is 0.1 or more
- BSA touches the inner surface of the membrane, and after passing through the membrane, moves while contacting the outer surface of the membrane.
- the inner surface and outer surface of the pores are also surface areas.
- the sieving coefficient of BSA is less than 0.1, BSA hardly permeates the membrane and does not come into force contact with the inner surface of the membrane, so the inner surface of the membrane is the surface area.
- the BSA sieve coefficient is calculated by the following equation.
- (a) is the BSA sieving coefficient
- (b) is the BSA concentration of the filtrate
- (c) is the BSA concentration of the stock solution before membrane separation
- (d) is the BSA concentration of the stock solution after membrane separation.
- the contact time is too short, it may be before the adsorption equilibrium is reached. On the other hand, if it is too long, the protein may be denatured. Also, if the amount of BSA solution is too small, the absolute amount of protein will decrease, so it should be performed at 50 ⁇ 1 or more per lcm 2 membrane area. In addition, since the amount of adsorption is greatly affected by temperature, the BSA solution and substrate must be contacted at 25 ° C.
- the following method is exemplified as a method of quantifying the amount of adsorbed BSA.
- the substrate is immersed in 50 ml of PBS twice for 10 seconds, washed, then immersed in 50 vol% aqueous acetic acid in the range of 1 ml to 30 ml for 12 hours at room temperature, and the acetic acid aqueous solution is freeze-dried.
- dry BSA is dissolved in an aqueous solution containing a blocking agent, and this solution is used for quantification. Quantification of BSA in solution is BETHYL Bovine
- hydrophilic domains are present on the surface of the protein molecule. It exists and exists inside the hydrophobic domain protein. It is thought that when a protein comes into contact with a hydrophobic substrate, the hydrophobic domain inside is exposed on the surface and adsorbed on the substrate by hydrophobic interaction. Therefore, it is effective to make the substrate surface hydrophilic in order to suppress protein adsorption.
- a hydrophilic polymer is grafted onto the substrate surface, protein adsorption due to the excluded volume effect due to the micro-Brownian motion of the hydrophilic polymer chain extended into the protein solution in addition to the hydrophilic effect due to the hydrophilic polymer. It is preferable because a suppression effect can be expected.
- the hydrophilization treatment is a treatment for imparting hydrophilicity to the surface of the substrate.
- a hydrophilic function is applied to the surface of the substrate by a method of mixing a hydrophilic compound into the raw material of the substrate, a chemical reaction or radiation irradiation.
- the method of grafting the hydrophilic polymer by irradiation is preferable because it is easy to control the hydrophilicity by selecting the kind and molecular weight of the hydrophilic polymer, and there are few by-products and sterilization can be performed at the same time. .
- the hydrophilic functional group is a functional group that generates a weak bond with a water molecule by electrostatic interaction or hydrogen bonding.
- examples thereof include, but are not limited to, a hydroxyl group, a carboxyl group, an amino group, a nitro group, an aldehyde group, a thiol group, a sulfonic acid group, a sulfuric acid group, and an aminosulfuric acid group.
- the hydroxyl group is preferred because it is a nonionic functional group that has a small interaction with a protein having a strong surface charge and a small acid-reducing ability, so that the denaturation of the protein is also small.
- the hydrophilic polymer refers to a polymer that is soluble in water and a polymer that can weakly interact with water molecules by electrostatic interaction or hydrogen bonding even though it is insoluble in water.
- other monomers such as a copolymer, a graft, and the like.
- polyvinyl alcohol or polyvinyl alcohol copolymer is particularly preferable because of its high effect.
- a polymer containing 10% or more and less than 100% of the butyl alcohol unit as the monomer repeating unit with respect to the total number of monomer repeating units is preferable.
- the polyvinyl alcohol copolymer includes a copolymer having a monomer repeating unit represented by the chemical structural formula of formula (1) and a monomer repeating unit represented by the chemical structural formula of formula (2) in the molecule.
- the other copolymerization component may be contained.
- the Ken degree is a numerical value obtained by Equation (2).
- the degree of keniness is low, the hydrophilicity tends to be low and the solubility in water tends to be low, so that it is difficult to surface-treat the base material as an aqueous solution, preferably 0.70 or more, more preferably 0.74 or more, more preferably 0.78 or more and less than 1.
- the degree of saponification is 1, it becomes polybulal alcohol, which is also a preferred embodiment as described above.
- the polymer may be a random copolymer, an alternating copolymer, a block copolymer, or a graft copolymer, or a combination thereof.
- the molecular weight of the hydrophilic polymer is small, and the molecular mobility of the hydrophilic polymer is small.
- the weight average molecular weight is preferably 1000 or more, more preferably 5000 or more, and further preferably 10,000 or more.
- the substrate is brought into contact with a hydrophilic polymer solution having a hydroxyl group, preferably an aqueous solution, and grafted there by radiation.
- a hydrophilic polymer solution having a hydroxyl group preferably an aqueous solution
- radiation ⁇ rays, ⁇ 8 rays, ⁇ rays, X rays, ultraviolet rays, electron rays, etc. are used. If the fractionation device is stored for a long period of time, bacteria may be generated and the performance may be reduced.
- the dose is preferably 15 kGy or more, but when sterilization is not required, it is preferable to perform the treatment within the range of 0.5 kGy or more and 200 kGy or less from the viewpoint of hydrophilization efficiency and prevention of deterioration of the substrate. More preferably, it is performed in the range of 1 kGy to lOOkGy.
- a flat membrane type separation membrane such as a flat filter, a cartridge type filter, a hollow fiber or the like
- Any hollow fiber separation membrane can be used, but in general, hollow fibers can be used most efficiently because they have a large membrane surface area per treatment liquid and can reduce pressure loss.
- a smaller hollow fiber inner diameter is preferable.
- the force S is preferably 1000 m or less, more preferably 500 m or less.
- the flat filter has the advantage that it can be easily formed at a low cost.
- Membrane materials include senorelose, cenololose acetate, polycarbonate, polysenolephone, polymethalate such as polymethylolate, polyacrylate, polyamide, poly (vinylidene fluoride), polyacrylonitrile, polyester, polyurethane, polystyrene, polyethylene and polypropylene. Examples thereof include materials selected from one or more kinds selected from the group consisting of these derivatives. Among these, polysulfone, which is often used in dialysis machines in recent years, is a fraction. The material is preferred because of its good characteristics.
- a 1000 g / ml BSA solution was prepared by dissolving 100 mg of ALBUMIN, BOVINE (A-7906, Lot. 41kl270) manufactured by SIGMA in PBSlOOml. 2 ml of the BSA solution was placed in a collection container, capped so that the solution did not evaporate, and allowed to stand at 25 ° C. for 4 hours. At this time, the BSA solution contacts 4.0 cm 2 on the inner surface of the collection container, and the amount of BSA adsorption is calculated using this area. The BSA solution in the collection container was removed by suction with an aspirator and washed 5 times with 3 ml of PBS.
- the mini-module has an inner diameter of about 5mm and a length of about 12cm.
- a general hollow fiber membrane type dialyzer it has two ports (blood ports) connected to the inside of the hollow fiber membrane and two ports (dialysate ports) connected to the outside.
- the hollow fiber membrane of the mini module and the inside of the module were washed with distilled water. Thereafter, PBS was injected from the dialysate port and then capped, and the outside of the hollow fiber was filled with PBS.
- One of the blood ports was connected to a silicon tube, and a peristaltic pump was installed along the way.
- a silicone tube was connected to the other blood port.
- the open ends of these two silicon tubes were inserted into PP tubes (188261) manufactured by GreinerBio-One.
- PP tubes (188261) manufactured by GreinerBio-One.
- SIGMA ALBU MIN To the PP tube, SIGMA ALBU MIN,
- BOVINE (A-7906, Lot. 41kl270) was dissolved in PBSlOOml, 10 ml of 1000 ⁇ gZml BSA solution was added, and circulated at 25 ° C for 4 hours at a flow rate of lml / min with a peristaltic pump. Thereafter, 300 ml of PBS was quickly fed by a peristaltic pump at a flow rate of lOml / min. At this time, the PBS from which the silicone tube was also discharged was discarded and not circulated.
- PBS in the mini-module was removed.
- the mini module was disassembled and the hollow fiber was taken out.
- the length of the extracted hollow fiber was 15 cm.
- the hollow fiber was cut to a length of lcm, and the entire amount was put into a PP tube (188261) manufactured by GreinerBio-One, 5 ml of 50% by volume acetic acid aqueous solution was added, and the mixture was allowed to stand at 25 ° C. for 12 hours. Thereafter, the hollow fiber was separated by filtration, and the acetic acid solution was lyophilized together with the collection container.
- a polyvinyl alcohol copolymer aqueous solution was prepared. Production 50 ml of the polybulualcohol aqueous solution was added to a bag with a chuck made by Japan Co., Ltd. (U-Pack E-4), and a 5 ml polystyrene round tube (352054) made by BECTONDICKINSON was immersed therein and irradiated with ⁇ rays.
- the absorbed dose of ⁇ rays was 26 kGy.
- the polystyrene round tube was washed with 1 liter of ultrapure water and dried in an oven at 50 ° C for 3 hours to obtain a collection container (1).
- a BECTON DICKINSON 5 ml polystyrene round tube (352054) was used as it was as a collection container (2).
- the resin-bonded portions at both ends of the module of a dialyzer BSl. 8L (Lot. 20440312) manufactured by Toray Industries, Inc. were cut to obtain a hollow fiber membrane.
- the resulting hollow fiber membrane has an inner diameter of 200 m. The thickness was 40 / zm.
- 100 hollow fiber membranes were bundled, and both ends were fixed to a glass tube module case with an epoxy-based potting agent so as not to block the hollow portion of the hollow fiber membrane, and a mini module was prepared.
- the mini-module has an inner diameter of about 5 mm and a length of about 17 cm.
- a general hollow fiber membrane dialyzer it has two ports (blood ports) connected to the inside of the hollow fiber membrane and ports connected to the outside. 2 dialysate ports.
- the hollow fiber membrane of the mini module and the inside of the module were washed with distilled water. Thereafter, PBS was filled to obtain a hollow fiber membrane minimodule (hereinafter abbreviated as minimodule (1)).
- mini-module (2) 40 hollow fiber membranes cut from Toray's dialyzer BS1.8L are bundled, and both ends are fixed to the glass tube module case with an epoxy potting agent so that the hollow portion of the hollow fiber membrane is not blocked.
- the mini-module has an inner diameter of about 5 mm and a length of about 17 cm.
- two external ports blood ports
- Polysulfone Solvay Udel (registered trademark) P-3500) 18 parts by weight and polybutyrrolidone (BASF K30) 9 parts by weight N, N, -dimethylacetamide 72 parts by weight and water 1 part by weight
- This film-forming stock solution was discharged from an outer tube of an orifice type double cylindrical die having an outer diameter of 0.3 mm and an inner diameter of 0.2 mm.
- As a core solution 58 parts by weight of N, ⁇ '-dimethylacetamide and 42 parts by weight of water were discharged from the inner tube.
- the discharged membrane forming stock solution passed through a distance of 350 mm from the base to the coagulation bath liquid level, and was then introduced into a 100% water coagulation bath to obtain a hollow fiber membrane.
- a hollow fiber membrane When the structure of the obtained hollow fiber membrane was confirmed with an electron microscope (Hitachi S800), it had an asymmetric structure. 10000 hollow fiber membranes obtained were inserted into a cylindrical plastic case having a dialysate inlet and a dialysate outlet in the same manner as a general dialyzer, and both ends were sealed with grease to obtain an effective membrane. Area 1.6 An m 2 hollow fiber membrane module was prepared. After washing this hollow fiber membrane module with water, 100 hollow fiber membranes were cut out from the module to prepare 100 pieces.
- minimodule (3) a hollow fiber membrane minimodule for concentration
- a mini module was manufactured in the same manner as the mini module (1). However, the hollow fiber membrane of the mini-module and the distilled water inside the module have not been cleaned until the BPS is filled.
- the blood was inserted from one blood port on the inner side of the thread membrane, passed through the hollow thread, taken out from the other blood port, put into a dialysate port on the blood port side through the tube, and exited from the other dialysate port.
- ⁇ -rays were irradiated with the polybulul alcohol filled inside and outside the hollow fiber of the mini-module, with the four ports sealed, and at this time the absorbed dose of ⁇ -rays was 26 kGy. .
- the hollow fiber membrane of the mini module and the inside of the module were washed with 3 L of 40 ° C distilled water.
- mini-module (4) a hollow fiber membrane mini-module (hereinafter abbreviated as mini-module (4)).
- a mini module was manufactured in the same manner as the mini module (2). However, the hollow fiber membrane of the mini-module and the distilled water inside the module have not been cleaned until the BPS is filled.
- a flow rate of 10 ml from one blood port inside the mini-module hollow fiber membrane, through the hollow fiber, from the other blood port, and through the tube to the dialysate port on the blood port side. From the dialysate port.
- ⁇ -rays were irradiated with the polybulul alcohol filled inside and outside the hollow fiber of the mini-module, with the four ports sealed, and at this time the absorbed dose of ⁇ -rays was 26 kGy. .
- the hollow fiber membrane of the mini module and the inside of the module were washed with 3 L of 40 ° C distilled water.
- minimodule (5) a hollow fiber membrane minimodule
- a mini module was manufactured in the same way as the mini module (3). However, the hollow fiber membrane of the mini-module and the distilled water inside the module have not been cleaned until the BPS is filled.
- the blood was put in from one blood port on the inner side, passed through the hollow yarn, taken out from the other blood port, put into a dialysate port on the blood port side through a tube, and taken out from the other dialysate port. Then, ⁇ -rays were irradiated with the polybulal alcohol aqueous solution filled inside and outside the hollow fiber of the mini-module and the four ports were sealed. At this time, the absorbed dose of ⁇ -rays was 26 kGy. .
- minimodule (6) The hollow fiber membrane of the mini-module and the inside of the module were washed with 3 L of distilled water at 40 ° C. Thereafter, PBS was filled to obtain a hollow fiber membrane minimodule for concentration (hereinafter abbreviated as minimodule (6)).
- one mini-module (1) was prepared, one of the outer ports was capped, and the other was connected with a silicone tube.
- the stock solution inlet and outlet were connected by a silicone tube to form a solution circulation circuit, and a peristaltic pump was provided in the circuit so that the solution could be circulated.
- a three-way valve in the middle of the solution circulation circuit An infusion pump was installed in one direction of the three-way valve. This was the first stage membrane separation unit.
- one of the mini modules (2) was capped on one of the outer ports, and the other one was connected with a silicone tube.
- One of the outer ports of the mini-module (3) was capped, and one was the filtrate outlet.
- the liquid inside the hollow fiber membrane of this mini-module (3) was also connected to the module stock solution inlet and outlet with a silicone tube to form a solution circulation circuit so that the stock solution could be circulated using a peristaltic pump.
- Two three-way nozzles were installed in the middle of the solution circulation circuit. This was used as the concentration membrane unit.
- the treatment liquid recovery port of the third-stage mini-module and the three-way valve of the concentration membrane unit were joined with a silicone tube.
- a treatment liquid recovery port of the concentration unit with a three-way pressure is provided, and only the solution circulation circuit is opened during the concentration operation.
- a storage container (1) is provided at the tip of the treatment liquid recovery port. The entire system was filled with PBS, and a composite system was created in which a membrane separation unit that fractionated proteins above albumin by molecular sieving and a protein concentration unit were directly connected.
- FIG. 1 is a schematic diagram of the separation system used in Example A1.
- the liquid flow is indicated by arrows.
- Serum and diluent (PBS) were injected into the first-stage solution circulation circuit 102 via the injection pump 100 and the three-way valve 101.
- the clarified liquid is fed by the first-stage pump 103, injected into the first separation membrane module 105 (mini module (1)), and the first-stage solution circulation.
- the circuit 102 was circulated.
- the solution treated in the first membrane separation unit was obtained from the treatment liquid recovery port 104 of the first membrane separation unit of the membrane separation membrane unit.
- this solution passes through the three-way valve 201 of the second-stage membrane separation unit, and is further fed into the second-stage solution circulation circuit 202 by the second-stage pump 203, so that the second separation membrane module 205 It was injected into (first minimodule (2)) and circulated through the second stage solution circulation circuit 202.
- the solution treated by the second membrane separation unit was obtained from the treatment liquid collection port 204 of the second stage membrane separation unit of the second stage membrane separation unit of the treatment liquid collection port.
- this solution passes through the three-way valve 301 of the third-stage membrane separation unit, and is further fed into the third-stage solution circulation circuit 302 by the third-stage pump 303, and the third separation membrane module 305 (second The mini-module (2)) was circulated through the solution circulation circuit 302.
- the liquid treated in the third membrane separation unit was obtained from the treatment liquid recovery port 304 of the third stage membrane separation membrane unit. Further, this processing solution passes through the three-way valve 401 of the concentration membrane unit, and is further fed into the fourth-stage solution circulation circuit 402 by the fourth-stage pump 403, and the concentrated membrane module 405 (mini module (3)). The 4th stage solution circulation circuit 402 was circulated. At that time, the liquid that has permeated from the concentrated membrane module 405 is taken out from the filtrate outlet 404 of the concentrated membrane unit and discarded. After completion of the permeation and concentration operation, the solution remaining in the fourth stage solution circulation circuit 402 of the mini-module (3) is opened to the collection container 407 (collection container (1)) by opening the three-way nozzle 406 of the concentration unit. To be taken out.
- the amount of albumin in the liquid obtained in the collection container 407 was 0.336 g
- the amount of ⁇ 2 microglobulin was 0.853 g
- the human used as the stock solution ⁇ albumin content in serum is 31200 ⁇ ⁇
- ⁇ 2- Mikurogurobu While maintaining the amount of phosphorus, albumin could be significantly removed.
- recovery container (1) is 16.6ng / cm 2
- hollow fiber strength of mini-module (2) 3 ⁇ 478.4 ng / cm 2 and the hollow fiber of the minimodule (3) was 429.3 ng / cm 2 .
- one mini-module (4) was prepared, one of the outer ports was capped, and the other was connected with a silicone tube.
- the stock solution inlet and outlet were connected by a silicone tube to form a solution circulation circuit, and a peristaltic pump was provided in the circuit so that the solution could be circulated.
- a three-way valve was provided in the middle of the solution circulation circuit, and an injection pump was attached in one direction of the three-way valve. This was the first stage membrane separation unit.
- one of the mini modules (5) was capped on one of the outer ports, and the other one was connected with a silicone tube.
- One of the outer ports of the mini-module (6) was capped, and one was the filtrate outlet.
- the liquid inside the hollow fiber membrane of this mini module (6) was also connected to the module's stock solution inlet and outlet with a silicone tube to form a solution circulation circuit so that the stock solution could be circulated using a peristaltic pump.
- Two three-way nozzles were installed in the middle of the solution circulation circuit. This was used as the concentration membrane unit.
- the amount of albumin in the liquid obtained in the collection container (1) was 0.251 ⁇ g
- the amount of ⁇ 2 immunoglobulin was 0.981 ⁇ g
- albumin in human serum used as the stock solution The amount was 31,200 g
- the amount of j82-microglobulin was 1.19 ⁇ g. While maintaining the amount of ⁇ 2-microglobulin, albumin could be removed significantly.
- the collection container were identified amount of adsorbed BSA (1) is 17.6ng / cm 2, hollow fiber strength 3 ⁇ 45.6ng / cm 2 of mini-module (4), hollow fiber mini-module (5) The hollow fiber of 39.2 ng / cm 2 and mini-module (6) was 42.8 ng / cm 2 .
- a filtration operation for 4 hours was carried out in the same manner as in Example A 1 except that the recovery container (2) was used instead of the recovery container (1) of Example A1.
- Albumin amount in the resulting liquid in collection container (2) is 0.490 g
- beta 2 microglobulin amount was 0.202 g
- the amount of albumin in human serum was used as stock solution 31200 ⁇ ⁇
- ⁇ 2- microglobulin amount was 1.19 ⁇ g and albumin could be removed, but the recovery of 13 2 -microglobulin was low.
- the collection container (2) was 236.4 ng / cm 2 , mini-module
- a polystyrene test tube (“5 ml Polystyren Round-B ottom made by BECTON DICKINSON”) is used to collect a solution containing fractionated trace proteins.
- ushi serum albumin in the present invention is BovineAlbumin Powder, Product Number A7906 manufactured by SIGMA, or an equivalent thereof.
- PBS Nasui Pharmaceutical Dulbecco PBS
- protein solution A protein solution
- the protein solution A prepared in the above was used for the adsorption experiment as follows. That is, as a control sample, a blocking agent (Dainippon Pharmaceutical Release Block Ace Cat.
- the ⁇ 2-MG concentration was measured using the ⁇ 2-MG measurement kit (Darazym ⁇ 2-m icrogloblin EIA TEST, Code. 305-11011, released by Wako Pure Chemical Industries, Ltd.) according to the manual attached to the kit.
- the amount of protein adsorbed was calculated by (Formula 5).
- Polystyrene test tube (“5ml Polystyrene Round-Bottom Tubej from BECTON DICKINSON”) and vinyl alcohol vinyl acetate copolymer (weight average molecular weight 10,000, saponification degree 80%, Aldrich Cat
- Example 2 The same polystyrene test tube initially prepared in Bl was immersed in 100 ml of Example Bl pobulle alcohol acetic acid butyl copolymer lOppm aqueous solution and irradiated with ⁇ rays. The absorbed dose of y-ray was 26 kGy. The polystyrene test tube was removed from the polyvinyl alcohol aqueous solution, washed with 500 ml of running water, and dried in an oven at 70 ° C for 1 hour. This test tube was subjected to a human ⁇ 2-microglobulin adsorption test. The results are shown in Table 3.
- Example 2 The same polystyrene test tube as that prepared first in Bl was immersed in 100 ml of polybulal alcohol (molecular weight 22000, Code No.28311-25, manufactured by Nacalai Tester) lOOOppm aqueous solution and irradiated with X-rays. The absorbed dose of gamma rays was 25 kGy.
- the polystyrene test tube was taken out of the polyvinyl alcohol aqueous solution, washed with 500 ml of running water, and dried in an oven at 70 ° C for 1 hour. This test tube was subjected to human j8 2-microglobulin adsorption test. The results are shown in Table 3.
- Example Bl The same polystyrene test tube as that initially prepared in Example Bl was immersed in 100 ml of a polyalcohol lOppm aqueous solution as in Example B3 and irradiated with ⁇ rays. The absorbed dose of gamma rays was 27 kGy.
- the polystyrene test tube was removed from the polyvinyl alcohol aqueous solution, washed with running water (500 ml), and dried in an oven at 70 ° C for 1 hour. This test tube was subjected to human j8 2_microglobulin adsorption test. The results are shown in Table 3.
- Polypropylene alcohol (molecular weight 10000, Aldrich Cat) from a polypropylene test tube (BECTON DICKINSON “5ml Polypropyrene Round- Bottom Tube”)
- No. 360627 It was immersed in 100 ml of lOOOOppm aqueous solution and irradiated with ⁇ rays. The absorbed dose of gamma rays was 25 kGy.
- the polystyrene test tube was removed from the polyvinyl alcohol aqueous solution, washed with 500 ml of running water, and dried in an oven at 70 ° C. for 1 hour. This test tube was subjected to human j8 2-microglobulin adsorption test. The results are shown in Table 3.
- Example B5 The same polypropylene test tube as initially prepared in Example B5 is the same as Example B5. It was immersed in 100 ml of lOppm aqueous solution of polybulal alcohol and irradiated with ⁇ rays. The absorbed dose of ⁇ rays was 25 kGy. The polystyrene test tube was removed from the polyvinyl alcohol aqueous solution, washed with 500 ml of running water, and dried in an oven at 70 ° C for 1 hour. This test tube was subjected to a human j82_microglobulin adsorption test. The results are shown in Table 3.
- Example B5 The polypropylene test tube prepared first in Example B5 was immersed in 100 ml of polybulol alcohol (molecular weight 22000, Code No.28311-25, manufactured by Nacalai Testa) lOOOOppm and irradiated with ⁇ rays. The absorbed dose of gamma rays was 26 kGy.
- the polystyrene test tube was removed from the polyvinyl alcohol aqueous solution, washed with 500 ml of running water, and dried in an oven at 70 ° C for 1 hour. This test tube was subjected to human j8 2-microglobulin adsorption test. The results are shown in Table 3.
- Example B8> The results are shown in Table 3.
- Example B5 The same polypropylene test tube as that prepared in Example B5 at the beginning was immersed in 100 ml of an aqueous polybutyl alcohol solution of lOppm as in Example B7 and irradiated with ⁇ rays. The absorbed dose of ⁇ rays was 27 kGy.
- the polystyrene test tube was removed from the polyvinyl alcohol aqueous solution, washed with 500 ml of running water, and dried in an oven at 70 ° C for 1 hour. This test tube was subjected to a human j82_microglobulin adsorption test. The results are shown in Table 3.
- Example B1 The same polystyrene test tube initially prepared in Example B1 was washed with 500 ml of running water and dried in an oven at 70 ° C. for 1 hour. This test tube was subjected to human j8 2-microglobulin adsorption test. The results are shown in Table 3.
- Example B5 The same polypropylene test tube initially prepared in Example B5 was washed with 500 ml of running water and dried in an oven at 70 ° C. for 1 hour. This test tube was subjected to a human j8 2-microglobulin adsorption test. The results are shown in Table 3.
- Example B1 The same polystyrene test tube initially prepared in Example B1 was immersed in 100 ml of polybulolpyrrolidone (molecular weight 50000, BASF Kollidon 25) lOOOOppm aqueous solution and irradiated with ⁇ rays. The absorbed dose of gamma rays was 25 kGy. Polystyrene pyrrolidone in water with polyvinylpyrrolidone The product was taken out from the solution, washed with 500 ml of running water, and dried in an oven at 70 ° C for 1 hour. This test tube was subjected to a human ⁇ 2-microglobulin adsorption test. The results are shown in Table 3.
- Example 2 The same polystyrene test tube initially prepared in Bl was immersed in 100 ml of polybulolpyrrolidone (molecular weight 3000, Kollidonl2PF, BASF) lOOOppm aqueous solution and irradiated with ⁇ rays. The absorbed dose of gamma rays was 27 kGy.
- the polystyrene test tube was taken out from the polyvinyl alcohol aqueous solution, washed with 500 ml of running water, and dried in an oven at 70 ° C for 1 hour. This test tube was subjected to a human ⁇ 2-microglobulin adsorption test. The results are shown in Table 3.
- Example 2 The same polystyrene test tube initially prepared in Example Bl was immersed in 100 ml of polyethylene glycol (molecular weight 20000, polyethylene glycol 20000 manufactured by Katayama Chemical Co., Ltd.) 1000 ppm aqueous solution and irradiated with ⁇ rays. The absorbed dose of gamma rays was 25 kGy.
- the polystyrene test tube was taken out of the polyvinyl alcohol aqueous solution, washed with 500 ml of running water, and dried in an oven at 70 ° C for 1 hour. This test tube was subjected to a human ⁇ 2-microglobulin adsorption test. The results are shown in Table 3.
- Example 2 The same polystyrene test tube initially prepared in Bl was immersed in 100 ml of polyethylene glycol (molecular weight 2000, polyethylene glycol 2000 manufactured by Wako Pure Chemical Industries) lOOOOppm aqueous solution and irradiated with ⁇ rays. The absorbed dose of gamma rays was 26 kGy.
- the polystyrene test tube was removed from the polyvinyl alcohol aqueous solution, washed with 500 ml of running water, and dried in an oven at 70 ° C for 1 hour. This test tube was subjected to human j8 2-microglobulin adsorption test. The results are shown in Table 3.
- Example 2 The same polystyrene test tube prepared initially in Bl was immersed in 100 ml of polyethyleneimine (molecular weight 25000, Aldrich Cat. Code 40872-7) lOOOppm aqueous solution and ⁇ -irradiated. The absorbed dose of gamma rays was 26 kGy. The polystyrene test tube was removed from the aqueous polyvinyl alcohol solution, washed with 500 ml of running water, and dried in an oven at 70 ° C for 1 hour. This test tube was subjected to a human 13 2-microglobulin adsorption test. The results are shown in Table 3. ⁇ Comparative Example B8>
- Example B1 The inner wall of the same polystyrene test tube initially prepared in Example B1 was washed with 15 ml of methanol and dried in an oven at 70 ° C. for 1 hour.
- the test tube was immersed in 100 ml of a 25000 ppm methanol solution of MPC and butyl methacrylate copolymer for 1 minute.
- the test tube was taken out of the polyhydroxyethyl methacrylate solution, and the solution in the test tube was discharged and dried in an oven at 70 ° C. for 1 hour.
- the test tube was washed with 500 ml of running water and dried in an oven at 70 ° C. for 1 hour.
- This test tube was subjected to human j8 2-microglobulin adsorption test. The results are shown in Table 3. Comparative Example 9>
- the inner wall of the same polypropylene test tube prepared initially in Example B5 was washed with 15 ml of methanol and dried in an oven at 70 ° C. for 1 hour.
- This test tube was immersed in 100 ml of a 25000 ppm methanol solution of MPC and butyl methacrylate copolymer for 1 minute.
- the test tube was taken out of the polyhydroxyethyl methacrylate solution, and the solution in the test tube was discharged and dried in an oven at 70 ° C. for 1 hour.
- the test tube was washed with 500 ml of running water and dried in an oven at 70 ° C. for 1 hour.
- This test tube was subjected to human j8 2-microglobulin adsorption test. The results are shown in Table 3.
- the fractionation device of the present invention is very useful in preparing a sample for performing proteome analysis, and can be used for the discovery of medicine, particularly human diseases.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Public Health (AREA)
- Urology & Nephrology (AREA)
- Veterinary Medicine (AREA)
- Vascular Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Anesthesiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Sampling And Sample Adjustment (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2578202A CA2578202C (en) | 2004-08-30 | 2005-08-30 | Fractionation apparatus |
JP2006532694A JP4910700B2 (ja) | 2004-08-30 | 2005-08-30 | 分画装置 |
US11/658,894 US20090191105A1 (en) | 2004-08-30 | 2005-08-30 | Fractionation Apparatus |
EP05781472.5A EP1785431B1 (en) | 2004-08-30 | 2005-08-30 | Fractionation apparatus |
CN2005800292615A CN101010334B (zh) | 2004-08-30 | 2005-08-30 | 分级装置 |
US12/834,666 US20110009503A1 (en) | 2004-08-30 | 2010-07-12 | Fractionation apparatus |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-250417 | 2004-08-30 | ||
JP2004250417 | 2004-08-30 | ||
JP2005-060269 | 2005-03-04 | ||
JP2005060269 | 2005-03-04 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/834,666 Division US20110009503A1 (en) | 2004-08-30 | 2010-07-12 | Fractionation apparatus |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006025352A1 true WO2006025352A1 (ja) | 2006-03-09 |
Family
ID=36000004
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/015704 WO2006025352A1 (ja) | 2004-08-30 | 2005-08-30 | 分画装置 |
Country Status (7)
Country | Link |
---|---|
US (2) | US20090191105A1 (ja) |
EP (1) | EP1785431B1 (ja) |
JP (1) | JP4910700B2 (ja) |
KR (1) | KR20070058463A (ja) |
CN (1) | CN101010334B (ja) |
CA (1) | CA2578202C (ja) |
WO (1) | WO2006025352A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008102744A1 (ja) | 2007-02-20 | 2008-08-28 | Toray Industries, Inc. | 樹脂成型体の製造方法 |
JP2017077240A (ja) * | 2015-10-21 | 2017-04-27 | 株式会社日本触媒 | 接着性細胞培養用基材、ならびにこれを利用した細胞培養容器および細胞培養方法 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2987514B1 (en) * | 2013-04-19 | 2022-12-21 | Asahi Kasei Medical Co., Ltd. | Hollow fiber membrane for blood treatment |
KR102400741B1 (ko) * | 2016-08-31 | 2022-05-23 | 도레이 카부시키가이샤 | 의료용 재료, 의료용 분리막, 및 혈액 정화기 |
CN112592399B (zh) * | 2020-12-15 | 2024-04-12 | 甘肃养泰和生物科技有限公司 | 一种从牛血清中分离牛血清白蛋白的制备方法及装置 |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5840323A (ja) | 1981-09-03 | 1983-03-09 | Idemitsu Petrochem Co Ltd | 潤滑特性のすぐれたグラフト共重合物の製造方法 |
JPS6426656A (en) * | 1987-06-03 | 1989-01-27 | Pall Corp | Activated medium low in non-specific protein adsorbability |
JPH02203933A (ja) * | 1989-01-30 | 1990-08-13 | Japan Atom Energy Res Inst | 染料を有するアフィニティ吸着剤の製造方法 |
JPH02222424A (ja) * | 1989-02-23 | 1990-09-05 | Asahi Chem Ind Co Ltd | カチオン選択吸着性多孔膜とその製造方法 |
JPH05262664A (ja) * | 1991-11-12 | 1993-10-12 | Asahi Chem Ind Co Ltd | 血液凝固第viii因子の吸着材 |
JPH1059863A (ja) * | 1996-08-19 | 1998-03-03 | Fujimori Kogyo Kk | アンチトロンビンiiiの分離精製方法 |
WO2000027496A1 (en) | 1998-11-09 | 2000-05-18 | Knut Irgum | A chromatography method and a column material useful in said method |
JP2000351814A (ja) * | 1996-02-05 | 2000-12-19 | Hiroshi Handa | 新規重合体及びこれを用いた物質のスクリーニング方法 |
JP3297707B2 (ja) | 1993-02-01 | 2002-07-02 | 旭メディカル株式会社 | 改質中空糸およびその製造方法 |
JP2002542163A (ja) | 1999-04-12 | 2002-12-10 | グラディポア リミテッド | 血漿成分の分離 |
US20030068317A1 (en) | 2001-04-20 | 2003-04-10 | William Lee | High capacity methods for separation, purification, concentration, immobilization and synthesis of compounds and applications based thereupon |
JP2003130882A (ja) | 2001-10-25 | 2003-05-08 | Sumitomo Bakelite Co Ltd | 蛋白質分析用微小回路 |
WO2004026931A2 (en) | 2002-09-18 | 2004-04-01 | Emembrane, Inc. | Functionalized materials and methods of using same |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2529756A (en) * | 1945-01-17 | 1950-11-14 | James L Bacus | Device for cleaning radiators |
JPS61161103A (ja) * | 1985-01-10 | 1986-07-21 | Terumo Corp | 親水性多孔質膜およびその製法 |
US4966848A (en) * | 1988-02-08 | 1990-10-30 | The General Hospital Corporation | Isolation, purification, characterization, cloning and sequencing of N α-acetyltransferase |
CA1314666C (en) * | 1988-06-13 | 1993-03-23 | Kazuo Toyomoto | Selectively ion-adsorptive, porous membrane |
US6309822B1 (en) * | 1989-06-07 | 2001-10-30 | Affymetrix, Inc. | Method for comparing copy number of nucleic acid sequences |
US5102393A (en) * | 1989-07-17 | 1992-04-07 | Survival Technology, Inc. | Autoinjector converted from intramuscular to subcutaneous mode of injection |
US5223421A (en) * | 1989-10-25 | 1993-06-29 | The General Hospital Corporation | Identification of methionine Nα-acetyltransferase |
US5187010A (en) * | 1990-11-27 | 1993-02-16 | W. R. Grace & Co.-Conn. | Membrane having high affinity for low density lipoprotein-cholesterol from whole blood |
JP3117575B2 (ja) * | 1992-04-29 | 2000-12-18 | 株式会社クラレ | ポリスルホン系中空繊維膜とその製造方法 |
DE9418715U1 (de) * | 1994-11-23 | 1995-01-12 | Carl Zeiss Jena Gmbh, 07745 Jena | Steuerbare Horizontblende für Planetarien |
JP3651121B2 (ja) * | 1995-06-30 | 2005-05-25 | 東レ株式会社 | 選択透過性分離膜 |
US5688489A (en) * | 1995-09-15 | 1997-11-18 | Resolution Pharmaceuticals, Inc. | Non-receptor mediated imaging agents |
US6545132B1 (en) * | 1996-02-05 | 2003-04-08 | Hiroshi Handa | Microsphere containing glycidyl methacrylate covered polymer and spacer coupled compound for isolating substances |
US6703207B2 (en) * | 1996-02-05 | 2004-03-09 | Hiroshi Handa | Method of screening substances with a glycidyl methacrylate covered styrene-glycidyl methacrylate polymer |
US5912014A (en) * | 1996-03-15 | 1999-06-15 | Unigene Laboratories, Inc. | Oral salmon calcitonin pharmaceutical products |
JP3379963B2 (ja) * | 1996-03-18 | 2003-02-24 | 日東電工株式会社 | 逆浸透複合膜及びこれを用いた水の逆浸透処理方法 |
CA2180786C (en) * | 1996-07-02 | 2008-05-27 | David Lightfoot | Plants containing the gdha gene and methods of use thereof |
GB9617021D0 (en) * | 1996-08-13 | 1996-09-25 | Salpep Biotechnology Inc | Novel peptides for treatment of inflammation and shock |
NZ337364A (en) * | 1997-02-15 | 2001-06-29 | Millennium Pharm Inc | Treatment of infarcts, ischemia and reperfusion through inhibition of NFkappaB |
DE19735587B4 (de) * | 1997-08-16 | 2012-03-22 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Peptid mit radioprotektiver Wirkung, dieses enthaltende kosmetische oder pharmazeutische Zusammensetzung, für dieses kodierende Nukleinsäure, Herstellungsverfahren für dieses Peptid und die Verwendung als radioprotektives Agens |
ATE338118T1 (de) * | 1997-12-12 | 2006-09-15 | Univ Western Ontario | Neues peptid, apoep1.b, zusammensetzungen und verwendungen davon |
US20040202645A1 (en) * | 2003-04-08 | 2004-10-14 | Khan Nisar Ahmed | Administration of gene-regulatory peptides |
US6921751B1 (en) * | 1998-05-20 | 2005-07-26 | Erasmus Universiteit Rotterdam | Immunoregulator |
US8680059B2 (en) * | 1998-05-20 | 2014-03-25 | Biotempt B.V. | Oligopeptide acetate and formulations thereof |
RU2139085C1 (ru) * | 1998-06-23 | 1999-10-10 | Санкт-Петербургская общественная организация "Институт биорегуляции и геронтологии" | Средство, стимулирующее репаративные процессы, и способ его применения |
JP2001205057A (ja) * | 2000-01-27 | 2001-07-31 | Toyobo Co Ltd | 中空糸膜 |
EP1300418A1 (en) * | 2001-10-04 | 2003-04-09 | Erasmus Universiteit Rotterdam | Gene regulation by oligopeptides |
US7576174B2 (en) * | 2000-03-29 | 2009-08-18 | Biotempt B.V. | Compositions capable of reducing elevated blood urea concentration |
US7358330B2 (en) * | 2001-03-29 | 2008-04-15 | Biotempt B.V. | Immunoregulatory compositions |
US6586403B1 (en) * | 2000-07-20 | 2003-07-01 | Salpep Biotechnology, Inc. | Treating allergic reactions and inflammatory responses with tri-and dipeptides |
US7316819B2 (en) * | 2001-03-08 | 2008-01-08 | Unigene Laboratories, Inc. | Oral peptide pharmaceutical dosage form and method of production |
US6894028B2 (en) * | 2001-04-06 | 2005-05-17 | Zengen, Inc. | Use of KPV tripeptide for dermatological disorders |
US7172739B2 (en) * | 2001-05-22 | 2007-02-06 | University Of Vermont And State Agricultural College | Protein fractionation |
US20080242618A1 (en) * | 2001-12-21 | 2008-10-02 | Khan Nisar A | Stratification |
US7786084B2 (en) * | 2001-12-21 | 2010-08-31 | Biotempt B.V. | Treatment of burns |
US20080194489A1 (en) * | 2001-12-21 | 2008-08-14 | Khan Nisar A | Treatment of iatrogenic disease |
US20080242837A1 (en) * | 2001-12-21 | 2008-10-02 | Khan Nisar A | Peptide compositions |
US7501391B2 (en) * | 2001-12-21 | 2009-03-10 | Biotempt B.V. | Treatment of transplant survival |
US7560433B2 (en) * | 2001-12-21 | 2009-07-14 | Biotempt B.V. | Treatment of multiple sclerosis (MS) |
WO2004016653A2 (en) * | 2002-08-15 | 2004-02-26 | Leukotech A/S | Bactericidal, anti-apoptotic, pro-inflammatory and anti-inflammatory peptides of heparin-binding protein (hbp) or human neutrophil elastase |
ITTO20030039A1 (it) * | 2003-01-24 | 2004-07-25 | Fresenius Hemocare Italia Srl | Filtro per separare leucociti da sangue intero e/o da preparati derivati dal sangue, procedimento per la fabbricazione del filtro, dispositivo e utilizzazione. |
IL157772A (en) * | 2003-09-04 | 2016-06-30 | Bmr Solutions Ltd | Compounds containing oligopeptide derived from turtle larvae and their use to encourage mammalian hemophysis |
-
2005
- 2005-08-30 EP EP05781472.5A patent/EP1785431B1/en not_active Not-in-force
- 2005-08-30 JP JP2006532694A patent/JP4910700B2/ja not_active Expired - Fee Related
- 2005-08-30 CN CN2005800292615A patent/CN101010334B/zh not_active Expired - Fee Related
- 2005-08-30 WO PCT/JP2005/015704 patent/WO2006025352A1/ja active Application Filing
- 2005-08-30 KR KR20077004631A patent/KR20070058463A/ko not_active Application Discontinuation
- 2005-08-30 US US11/658,894 patent/US20090191105A1/en not_active Abandoned
- 2005-08-30 CA CA2578202A patent/CA2578202C/en not_active Expired - Fee Related
-
2010
- 2010-07-12 US US12/834,666 patent/US20110009503A1/en not_active Abandoned
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5840323A (ja) | 1981-09-03 | 1983-03-09 | Idemitsu Petrochem Co Ltd | 潤滑特性のすぐれたグラフト共重合物の製造方法 |
JPS6426656A (en) * | 1987-06-03 | 1989-01-27 | Pall Corp | Activated medium low in non-specific protein adsorbability |
JPH02203933A (ja) * | 1989-01-30 | 1990-08-13 | Japan Atom Energy Res Inst | 染料を有するアフィニティ吸着剤の製造方法 |
JPH02222424A (ja) * | 1989-02-23 | 1990-09-05 | Asahi Chem Ind Co Ltd | カチオン選択吸着性多孔膜とその製造方法 |
JPH05262664A (ja) * | 1991-11-12 | 1993-10-12 | Asahi Chem Ind Co Ltd | 血液凝固第viii因子の吸着材 |
JP3297707B2 (ja) | 1993-02-01 | 2002-07-02 | 旭メディカル株式会社 | 改質中空糸およびその製造方法 |
JP2000351814A (ja) * | 1996-02-05 | 2000-12-19 | Hiroshi Handa | 新規重合体及びこれを用いた物質のスクリーニング方法 |
JPH1059863A (ja) * | 1996-08-19 | 1998-03-03 | Fujimori Kogyo Kk | アンチトロンビンiiiの分離精製方法 |
WO2000027496A1 (en) | 1998-11-09 | 2000-05-18 | Knut Irgum | A chromatography method and a column material useful in said method |
JP2002542163A (ja) | 1999-04-12 | 2002-12-10 | グラディポア リミテッド | 血漿成分の分離 |
US20030068317A1 (en) | 2001-04-20 | 2003-04-10 | William Lee | High capacity methods for separation, purification, concentration, immobilization and synthesis of compounds and applications based thereupon |
JP2003130882A (ja) | 2001-10-25 | 2003-05-08 | Sumitomo Bakelite Co Ltd | 蛋白質分析用微小回路 |
WO2004026931A2 (en) | 2002-09-18 | 2004-04-01 | Emembrane, Inc. | Functionalized materials and methods of using same |
Non-Patent Citations (3)
Title |
---|
ANDERSON NL; ANDERSON NG: "Molecular & Cellular Proteomics", vol. 1, 2002, THE AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, INC., article "The human plasmaproteome: history, character, and diagnostic prospects", pages: 845 - 867 |
See also references of EP1785431A4 |
THE JAPANESE BIOCHEMICAL SOCIETY,: "New Biochemical Experiments", vol. 1, 1990, TOKYO KAGAKUDOZIN CO., LTD., article "Proteins (1)separation-refining-characteristics" |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008102744A1 (ja) | 2007-02-20 | 2008-08-28 | Toray Industries, Inc. | 樹脂成型体の製造方法 |
JP2017077240A (ja) * | 2015-10-21 | 2017-04-27 | 株式会社日本触媒 | 接着性細胞培養用基材、ならびにこれを利用した細胞培養容器および細胞培養方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101010334A (zh) | 2007-08-01 |
CA2578202C (en) | 2013-12-17 |
EP1785431A4 (en) | 2011-06-08 |
JP4910700B2 (ja) | 2012-04-04 |
JPWO2006025352A1 (ja) | 2008-05-08 |
CN101010334B (zh) | 2013-02-06 |
KR20070058463A (ko) | 2007-06-08 |
US20090191105A1 (en) | 2009-07-30 |
US20110009503A1 (en) | 2011-01-13 |
CA2578202A1 (en) | 2006-03-09 |
EP1785431B1 (en) | 2016-01-20 |
EP1785431A1 (en) | 2007-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4655938B2 (ja) | 分画装置および分画方法 | |
JP4910700B2 (ja) | 分画装置 | |
JP2007252893A (ja) | 改質基材の製造方法 | |
JP2006343220A (ja) | 生体成分含有溶液の前処理方法および分析溶液精製方法 | |
JP4892824B2 (ja) | 中空糸膜型分離膜の製造方法ならびにその製造方法で製造された中空糸膜型分離膜の使用方法 | |
JP7199027B2 (ja) | 濃縮デバイス | |
CA2537209C (en) | Method of preparing solution having composition of biological components | |
JP2005156249A (ja) | 生体成分分離溶液 | |
JP2005232156A (ja) | 生体成分精製溶液、生体成分分離方法および生体成分分離装置 | |
JP2007003213A (ja) | 生体成分含有溶液の分離精製システムおよび分離精製方法 | |
RU2631934C1 (ru) | Сорбционная композитная мембрана и биосепарирующее устройство для выделения днк | |
JP2005320322A (ja) | 分画装置 | |
JP2006256995A (ja) | 生体成分精製溶液、生体成分分離方法および生体成分分離装置 | |
JP2005126376A (ja) | 生体成分精製溶液 | |
JP2005214919A (ja) | タンパク質および/もしくはペプチド分析前処理用分離膜 | |
JP2006089468A (ja) | タンパク質分画デバイス用緩衝液およびそれを用いるタンパク質の分画方法 | |
JP4649845B2 (ja) | 改質基材 | |
JP2006194724A (ja) | タンパク質および/もしくはペプチド分析前処理用分離膜 | |
JP4876416B2 (ja) | 分画装置および分画装置用カートリッジ | |
JP2005177573A (ja) | 分離システム | |
JP2006276009A (ja) | タンパク質分画デバイスおよびそれを用いるタンパク質の分画・回収方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006532694 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005781472 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11658894 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077004631 Country of ref document: KR Ref document number: 2578202 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580029261.5 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2005781472 Country of ref document: EP |